Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luveltamab tazevibulin in advanced NSCLC
NCT06555263Phase 2Withdrawn
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of luveltamab tazevibulin in non-small cell lung cancer (NSCLC), sponsored by Sutro Biopharma, Inc.. Planned start Aug 2024; status: withdrawn.
02
Drugs
luveltamab tazevibulin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06555263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555263.